Development of historic deacetylase inhibitors.

被引：0
|
作者：
Richon, VM [1 ]
机构：
[1] Aton Pharma Inc, Tarrytown, NY USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6272S / 6272S
页数：1
相关论文
共 50 条
  • [21] Development of potent and selective factor Xa inhibitors.
    Rai, R
    Kolesnikov, A
    Young, WB
    Sprengeler, PA
    Leahy, EM
    Li, Y
    Shrader, WD
    Burgess-Henry, J
    Sangalang, J
    Verner, EJ
    Allen, D
    Chen, X
    Elrod, KC
    Cregar, L
    Katz, BA
    Luong, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U9 - U9
  • [22] Quantitative structure activity relationship (QSAR) evaluations of the pharmacology and toxicology of histone deacetylase inhibitors.
    Schramm, U
    Thomas, H
    Atadja, P
    Remiszewski, S
    Wolf, A
    TOXICOLOGICAL SCIENCES, 2003, 72 : 38 - 38
  • [23] Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy
    Piekarz, Richard L.
    Sackett, Dan L.
    Bates, Susan E.
    CANCER JOURNAL, 2007, 13 (01): : 30 - 39
  • [24] Research Advances in the Use of Historic Deacetylase Inhibitors Epigenetic Targeting cif Cancer
    Bai, Yu
    Ahnlad, Daid
    Wang, Ting
    Cui, Guihua
    Li, Wenliang
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (12) : 995 - 1004
  • [25] Development of histone deacetylase inhibitors for cancer treatment
    Marchion, Douglas
    Muenster, Pamela
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 583 - 598
  • [26] Respiratory inhibitors.
    Dixon, M
    ARCHIV FUR EXPERIMENTELLE ZELLFORSCHUNG, 1934, 15 : 17 - 26
  • [27] Development of potent and selective caspase-3 inhibitors.
    Aspiotis, R
    Bayly, C
    Becker, JW
    Ethier, D
    Francouer, S
    Margarita, GC
    Giroux, A
    Grimm, EL
    Han, YX
    McKay, DJ
    Nicholson, DW
    Peterson, E
    Rasper, DM
    Renaud, J
    Rotonda, J
    Roy, S
    Tam, J
    Tawa, P
    Thornberry, NA
    Vaillancourt, J
    Xanthoudakis, S
    Zamboni, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U54 - U54
  • [28] 25 YEARS EXPERIENCE IN THE DEVELOPMENT AND APPLICATION OF SCALE INHIBITORS.
    Cooper, K.G.
    Hanlon, L.G.
    Smart, G.M.
    Talbot, R.E.
    Coating Conference, Proceedings of the Technical Association of the Pulp and Paper Industry, 1979, : 243 - 255
  • [29] Matrix metalloproteinases and their inhibitors. The role in the development of diabetic microangiopathy
    Klych, Agnieszka
    Kosowska, Agnieszka
    CLINICAL DIABETOLOGY, 2012, 1 (03): : 114 - 120
  • [30] Development of thienopyridines as VEGFR-2 kinase inhibitors.
    Munchhof, MJ
    Adams, MA
    Atherton, JA
    Beebe, JS
    Casavant, JC
    Cooper, BC
    Doty, JD
    Emerson, EE
    Foster, BF
    Gant, TG
    Garshasb, SG
    Goodwin, PG
    Harriman, SH
    Higdon, CH
    Hillerman, SH
    Interi, CI
    Jani, JJ
    Knauth, LK
    Marx, MM
    Natarajan, VN
    Noe, MN
    Rossi, AR
    Savage, DS
    Shaeffer, TS
    Smolarek, TS
    Snow, SS
    Sobolov, SS
    Soderstrom, ES
    Sun, JS
    Turncliff, RT
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U197 - U197
12345